Table 2 Prevalence of pre-transplant panel reactive antibody and donor-specific antibodies
|  | Recipients (n = 76) |
|---|---|
Total | Â |
cPRA | Â |
 Not detected | 41 (54.0) |
 PRA < 50% | 26 (34.2) |
 PRA ≥ 50% | 9 (11.8) |
Anti-HLA Ab (MFI) | Â |
  < 1000 | 45 (59.2) |
 1000 ≤ MFI < 3000 | 12 (15.8) |
 3000 ≤ MFI < 5000 | 7 (9.2) |
  ≥ 5000 | 12 (15.8) |
Class I | Â |
cPRA | Â |
 Not detected | 50 (65.8) |
 Class I PRA < 50% | 20 (26.3) |
 Class I PRA ≥ 50% | 6 (7.9) |
Anti-HLA Ab (MFI) | Â |
  < 1000 | 54 (71.1) |
 1000 ≤ MFI < 3000 | 11 (14.5) |
 3000 ≤ MFI < 5000 | 2 (2.6) |
  ≥ 5000 | 10 (13.2) |
Class II | Â |
cPRA | Â |
 Not detected | 54 (71.0) |
 Class I PRA < 50% | 18 (23.7) |
 Class I PRA ≥ 50% | 4 (5.3) |
Anti-HLA Ab (MFI) | Â |
  < 1000 | 59 (77.6) |
 1000 ≤ MFI < 3000 | 9 (11.8) |
 3000 ≤ MFI < 5000 | 6 (7.9) |
  ≥ 5000 | 3 (3.9) |